CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing targeted T cell immunotherapies for cancers driven by the ALK gene. By utilizing ALK-directed therapies, the aim is to eradicate residual cancer cells during the minimal residual disease phase, potentially leading to a cure for patients before relapse occurs.
Cancers driven by the oncogenic activation of the ALK gene include subsets of non-small cell lung cancer, lymphoma, neuroblastoma, melanoma, glioblastoma, thyroid cancer, stromal tumors and other hematologic malignancies and solid tumors.
Typically, these cancers affect children or young adults in healthy conditions with a long expectancy of life.
They are currently treated with ALK tyrosine kinase inhibitors (TKIs) either in first line or at relapse after other standard therapies. ALK TKIs redu…
UNIVERSITA DEGLI STUDI DI TORINO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
